Profound(US:PROF) Globenewswire·2026-02-12 13:30Core Insights - Profound Medical Corp. has been awarded the 2025/2026 Mount Logan Award for its achievements in interventional MRI procedures, particularly for the TULSA Procedure [1][2] Company Achievements - The company has treated its 4,000th TULSA Procedure patient and secured new U.S. reimbursement codes from Medicare, enhancing its market position [2] - Profound Medical has established strategic partnerships to expand global patient access to its technologies [2] - The TULSA Procedure is a significant advancement in prostate care, utilizing robotically controlled ultrasound and real-time MRI thermography for precise treatment [2][5] Technology Overview - The TULSA Procedure employs a unique method of delivering ultrasound from within the urethra to heat prostate tissue to 'kill temperature' (55-57°C), minimizing side effects and ensuring no procedural blood loss [2][5] - The procedure is incision-free, requires no overnight hospital stay, and allows for a quick recovery, making it a compelling option for patients [5] Market Position and Future Plans - Currently, there is only one TULSA-PRO system installed in Canada, but the company aims to increase installations following the regain of exclusive distribution rights in the country [3] - Profound Medical is deploying a direct sales team in North America and partnering with strategic distribution partners to enhance its global reach [3] Additional Products - Profound Medical is also commercializing Sonalleve, a therapeutic platform approved for treating uterine fibroids and other conditions, with potential applications in non-invasive cancer treatments [6]